Spruce Biosciences GAAP EPS of -$50.83 misses by $29.59

AI Briefing

• – Spruce Biosciences (SPRB) misses Q4 GAAP EPS by $29.59, cites $48.9M cash, runway to early 2027, TA-ERT BLA timeline.
• – Company notes strong cash position, expects to maintain operations through 2027.
• – Shares fall 4.9% pre-market following earnings report.